1stOncology™: Cancer Intelligence Service – Page 14383 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

NOXXON ANNOUNCES LEADING INTERNATIONAL PHARMA TO EVALUATE NOX-A12 IN NEW INDICATION

On June 24, 2019 NOXXON Pharma reported that a leading international pharmaceutical company amongst the top-10 pharmaceutical companies by worldwide revenue[1] has signed an agreement with NOXXON for the purpose of evaluating NOX-A12 in a new indication, which will remain undisclosed for competitive reasons (Press release, NOXXON, JUN 24, 2019, View Source [SID1234605506]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

"This agreement is an exceptional opportunity for NOXXON and a chance for NOX-A12 to deliver a broader therapeutic profile, while we continue to build value in our oncology pipeline in pancreatic, colorectal, and brain cancer and in our company," said Aram Mangasarian, CEO of NOXXON.

NOXXON will supply NOX-A12 to the pharmaceutical company, which will fund and conduct preclinical studies to assess NOX-A12 in an indication which is a serious disease with significant unmet medical need. The market for this indication has been valued at more than a billion Euros. The studies are anticipated to run approximately 10 months, after which the parties may enter negotiations for rights to NOX-A12. As part of the agreement with the pharmaceutical partner performing the studies, NOXXON will not disclose the results until any negotiations are complete. As part of the agreement the pharmaceutical company has certain rights to participate in negotiations regarding the intellectual property relating to NOX-A12.

Anwita entered collaboration with Junshi Biosciences, Co Ltd.

On 24 June 2019, Junshi Biosciences reported that they entered into a stock purchase agreement with Anwita Biosciences,Inc. ("Anwita"), pursuant to which the Company agreed to subscribe for 2,990,162 Series APreferred Stock in Anwita, representing approximately 20% of its outstanding shares, at a cashconsideration of US$10,000,000 (Press release, Anwita Biosciences, JUN 24, 2019, View Source [SID1234573150]). Anwita is a company headquartered in San Francisco Bay Area,focused on innovative protein engineering to generate best-in-class cytokines for immuno-oncology(IO).

The Company and Anwita also entered into a license agreement (the "License Agreement") on 24June 2019 for the Company to develop and commercialize Anwita’s AWT008, a novel IL-21 fusionprotein, in the greater China territories (including mainland China, Taiwan, Macau, and HongKong). In consideration of the grant of the license by Anwita, the Company agreed to pay Anwitaan aggregate of US$2 million in cash after execution of the License Agreement and completionof technology transfer of AWT008. Also under the License Agreement, if AWT008 fulfills therequirement for IND filing, the Company may approve to proceed to file the IND and to conductsubsequent clinical trials to get regulatory approval for its commercial sales. In such event, Anwitawill be eligible to receive up to US$64.5 million in aggregate in development milestones for theAWT008 program.

IL-21 is an active cytokine to stimulate the activation of innate and adaptive immune cells, suchas natural killer (NK) cells and cytotoxic T cells. AWT008 is Anwita’s proprietary IL-21 fusionprotein with a prolonged half-life and improved in vivo antitumor activities in animal models, andis intended for development as single agent or in combination with other therapeutic agents due toits proposed mechanism.

This foreign investment needs to be approved or filed by the Commission of Commerce, theNational Development and Reform Commission and other government departments. The Companywill actively handle the approval or filing procedures of the Commission of Commerce, theNational Development and Reform Commission and other government departments involved in thisforeign investment. However, there are still certain uncertainties as to whether such approval orfiling can be ultimately obtained.

Cautionary Statement required by Rule 18A.05 of the Listing Rules of the Stock Exchange:The Company may not be able to ultimately develop and market AWT008 successfully. Investorsare reminded to exercise caution.

Avid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2019 After Market Close on June 27, 2019

On June 24, 2019 Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, reported that it will report financial results for the quarter and fiscal year (FY) ended April 30, 2019 on June 27, 2019 after market close and will host a conference call and webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time) (Press release, Avid Bioservices, JUN 24, 2019, View Source [SID1234539008]). Members of Avid’s senior management will discuss financial results for the quarter and FY ended April 30, 2019 and review recent corporate developments.

To listen to the live webcast, or access the archived webcast, please visit: View Source

To listen to the conference call, please dial (877) 312-5443 or (253) 237-1126 and request the Avid Bioservices call.

8-K – Current reportEntry into a Material Definitive Agreement.

On June 24, 2019, Xenetic Biosciences, Inc. (the "Company"), in connection with its previously announced reverse stock split, reported that it entered into a consent agreement (the "Consent Agreement") with certain holders (the "Holders") of warrants to purchase shares of the Company’s common stock whose consent was required to effect the reverse stock split (Filing, 8-K, Xenetic Biosciences, JUN 24, 2019, View Source [SID1234537830]). In consideration of the Holders’ consent, the Company agreed to issue the Holders warrants (the "Consent Warrants") to purchase an aggregate of 100,000 shares of the Company’s common stock, on a pre-split basis, at an exercise price per share based on a volume weighted average price for the five trading days following the effectiveness of the reverse stock split, as further described in the Consent Warrants. On a post-split basis, the Company will issue Consent Warrants to purchase an aggregate of 8,335 shares of Company common stock to the Holders. Copies of the Consent Agreement and a form of the Consent Warrants are filed as Exhibit 10.1 and Exhibit 4.1 to this report and are incorporated herein by reference.

Bioasis Announces Allowances of Patent Applications in the U.S. and Europe Relating to xB3 Platform Technology and Key Therapeutic Indications

On June 24, 2019 Bioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF) (the "Company" or "Bioasis"), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TM platform technology for the delivery of therapeutics across the blood-brain barrier ("BBB") and the treatment of central nervous system ("CNS") disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, reported that the U.S. Patent and Trademark Office ("USPTO") and the European Patent Office ("EPO") have issued allowances of patent applications relating to xB3 technology (Press release, biOasis, JUN 24, 2019, View Source [SID1234537254]).

Both the USPTO and EPO have issued allowances of the Company’s patent applications relating to iduronate-2-sulfatase ("IDS") polypeptide / xB3 conjugates. The patent applications relate to the IDS/xB3 fusion conjugates as well as pharmaceutical compositions containing the fusion conjugates. The IDS/xB3 conjugates may be used in treating lysosomal storage diseases such as Hunter Syndrome.

The EPO has issued an allowance of the Company’s patent application relating to trastuzumab/xB3 fusion conjugates. The patent application relates to the trastuzumab/xB3 fusion conjugates as well as pharmaceutical compositions containing the fusion conjugates. The trastuzumab/xB3 conjugates may be used in treating a variety of diseases, for example, a HER2-overexpressing metastatic breast cancer.

"We are excited about the issuance of allowance of these patent applications by the USPTO and EPO, which enhance the strength of our intellectual property protection around our core assets, especially with respect to our lead program xB3-001, potential treatments for lysosomal storage disorders and our commercial licensing strategy," said Company Chair and Chief Executive Officer, Deborah Rathjen, Ph.D. "These patents reaffirm the overall value of Bioasis’ xB3 platform technology as we work to advance our programs for difficult-to-treat diseases of the central nervous system by delivering therapeutics across the blood-brain barrier."